Analyst consensus rating
Inhibrx Biosciences Analyst Rating: Strong Buy
Direct answer
Inhibrx Biosciences's consensus rating is Strong Buy.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $266.67.
Forecast evidence checked October 19, 2026.
Get free Inhibrx Biosciences email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $89.83
- Average price target
- $266.67
- High price target
- $325.00
- Low price target
- $230.00
- Low target gap
- +156%
- Target upside
- +196.9%
- High target gap
- +261.8%
- Target range width
- 105.8%
- Consensus rating
- Strong Buy
- Analysts
- 3
- Evidence date
- October 19, 2026
- Valid through
- October 26, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Inhibrx Biosciences?
Inhibrx Biosciences has a verified Strong Buy consensus. The same dataset has an average price target of $266.67.
How far are Inhibrx Biosciences's low and high targets from the recorded price?
The low target implies +156%, while the high target implies +261.8%.
How many analysts are included in Inhibrx Biosciences's consensus?
The verified consensus includes 3 analysts.
How is Inhibrx Biosciences's target upside or downside calculated?
The average target of $266.67 is divided by the recorded price of $89.83, then one is subtracted to produce +196.9%. This does not guarantee a future return.
When was Inhibrx Biosciences's analyst forecast verified?
The data was verified on 2026-10-19. The dataset is valid through 2026-10-26.